Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta‐Analysis
Brain and Behavior · 2026-11 · 16 (11)
DOI: 10.1002/brb3.71875 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Brain and Behavior, online erschienen am 11.11.2026. Verfasst von Ghazi Uddin Ahmed und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Fc. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Severe muscle weakness is a hallmark of generalized myasthenia gravis (gMG), a chronic autoimmune disease that severely reduces quality of life. Traditional immunosuppressive treatments can have significant adverse effects and only partially relieve symptoms. Clinical trials have demonstrated the potential of efgartigimod, a neonatal Fc receptor (FcRn) antagonist that lowers harmful IgG autoantibodies. This systematic review and meta‐analysis assessed its efficacy and safety, analyzing randomized controlled evidence separately from uncontrolled real‐world evidence.
Methods
Up until August 2025, we conducted a thorough search of PubMed, Scopus, and Web of Science, supplemented by the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov, for observational studies and randomized controlled trials (RCTs) evaluating efgartigimod in gMG. Improvement in myasthenia gravis activities of daily living (MG‐ADL), responder rates, adverse events, and quantitative myasthenia gravis (QMG) scores were the main outcomes. Placebo‐controlled RCTs were pooled in two‐arm meta‐analyses (primary evidence) and uncontrolled cohort studies and case series in single‐arm meta‐analyses (supportive evidence), using random‐effects models in Review Manager 5.4 and R (v4.4.2). Sensitivity, leave‐one‐out influence, and subgroup analyses were performed, 95% prediction intervals were calculated for single‐arm outcomes, and the certainty of evidence was rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The review was retrospectively registered in PROSPERO (CRD420261518373).
Results
We included 11 studies (two RCTs, six cohort studies, and three case series) comprising 480 participants (385 efgartigimod‐treated and 95 placebo‐treated). In the RCTs, efgartigimod improved MG‐ADL (mean differences [MD] = −2.62, 95% CI: −3.99 to −1.25, p = 0.0002) and QMG scores (MD = −4.59, 95% CI: −6.24 to −2.94, p < 0.00001) at peak effect, but the differences were not significant at the end of follow‐up. MG‐ADL responders were more frequent with efgartigimod than with placebo (risk ratios [RR] = 1.90, 95% CI: 1.40–2.56, p < 0.0001), including among acetylcholine receptor (AChR)‐Ab+ patients (RR = 2.37, 95% CI: 1.61–3.47, p < 0.0001). The incidence of adverse events did not differ from placebo (RR = 0.93, 95% CI: 0.81–1.07, p = 0.29). Certainty of evidence was moderate for peak‐effect, responder, and safety outcomes. In uncontrolled real‐world studies, responses were observed in AChR‐Ab+ and muscle‐specific tyrosine kinase (MuSK)‐Ab+ patients (MuSK‐Ab+ pooled proportion = 0.781, 95% CI: 0.499–0.927; 18 patients) and corticosteroid doses decreased, but this evidence was of very low certainty. Single‐arm estimates showed substantial to considerable heterogeneity ( I 2 up to 98.8%) and wide 95% prediction intervals, although every contributing study showed improvement in MG‐ADL and a reduction in corticosteroid dose. Randomized estimates were unchanged when restricted to the phase 3 ADAPT trial, which contributed 71%–92% of the statistical weight.
Conclusion
In randomized trials, efgartigimod produces clinically meaningful short‐term improvement in gMG with an adverse event incidence comparable to placebo. Because the benefit was not maintained at the end of follow‐up, cyclical, individualized retreatment is likely required. Real‐world data suggest benefit across serological subtypes and a corticosteroid‐sparing effect; however, these uncontrolled estimates were heterogeneous and of very low certainty, and larger, longer term controlled studies, ideally conducted independently of the manufacturer, are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
- Chandka Medical College, Larkana, Pakistan.
- Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Chandka Medical College, SMBBMU, Larkana, Pakistan.
- Department of Medicine, Kabul University of Medical Sciences Abu Ali Sina, Kabul, Afghanistan.
ORCID-Profile: Ghazi Uddin Ahmed, Fnu Ramsha, Sejal Kinger, Jawad Ghias Shaikh, Fnu Prejna, Fnu Ritik, Iqra Shabir, Faisal Suhail, Muhammad Abdul Basit, Muhammad Moiz, Amjad Ali, Abdul Manan, Abedin Samadi, Ahmed Asad Raza
Zitieren
APA
Ahmed, G. U., Ramsha, F., Kinger, S., Shaikh, J. G., Prejna, F., Ritik, F., Shabir, I., Suhail, F., Basit, M. A., Moiz, M., Ali, A., Manan, A., Samadi, A., & Raza, A. A. (2026). Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta‐Analysis. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71875
Vancouver
Ahmed GU, Ramsha F, Kinger S, Shaikh JG, Prejna F, Ritik F, et al. Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta‐Analysis. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71875
BibTeX
@article{Ahmed2026,
author = {Ahmed, Ghazi Uddin and Ramsha, Fnu and Kinger, Sejal and Shaikh, Jawad Ghias and Prejna, Fnu and Ritik, Fnu and Shabir, Iqra and Suhail, Faisal and Basit, Muhammad Abdul and Moiz, Muhammad and Ali, Amjad and Manan, Abdul and Samadi, Abedin and Raza, Ahmed Asad},
title = {Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta‐Analysis},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/brb3.71875}
}
EUVIMED